REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
REGENXBIO (Nasdaq: RGNX) presented positive data from the Phase II fellow eye sub-study of subretinal ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the American Academy of Ophthalmology (AAO) meeting. Key findings at nine months post-administration include:
- 97% reduction in annualized anti-VEGF treatment burden
- 100% of patients required either zero or one supplemental injection
- 78% of patients were completely injection-free
The treatment was well-tolerated with no drug-related serious adverse events and no cases of intraocular inflammation. Patients demonstrated sustained best-corrected visual acuity (BCVA) and central retinal thickness (CRT). The data highlight the potential of ABBV-RGX-314 as a one-time effective treatment option for patients with bilateral wet AMD.
REGENXBIO (Nasdaq: RGNX) ha presentato dati positivi dallo studio secondario sull'occhio compagno di Fase II del trattamento subretinale ABBV-RGX-314 in pazienti con degenerazione maculare legata all'età umida bilaterale (AMD umida) durante il congresso dell'American Academy of Ophthalmology (AAO). I risultati chiave a nove mesi dalla somministrazione includono:
- riduzione del 97% del carico annualizzato di trattamenti anti-VEGF
- 100% dei pazienti ha richiesto zero o un'iniezione supplementare
- 78% dei pazienti è stato completamente esente da iniezioni
Il trattamento è stato ben tollerato con nessun evento avverso grave correlato al farmaco e senza casi di infiammazione intraoculare. I pazienti hanno mostrato una sostanziale acuità visiva corretta (BCVA) e uno spessore retinico centrale (CRT) mantenuto. I dati evidenziano il potenziale di ABBV-RGX-314 come opzione terapeutica efficace in un'unica somministrazione per pazienti con AMD umida bilaterale.
REGENXBIO (Nasdaq: RGNX) presentó datos positivos del subestudio del ojo compañero de Fase II del tratamiento subretinal ABBV-RGX-314 en pacientes con degeneración macular húmeda bilateral relacionada con la edad (AMD húmeda) en la reunión de la American Academy of Ophthalmology (AAO). Los hallazgos clave nueve meses después de la administración incluyen:
- reducción del 97% en la carga anualizada de tratamiento anti-VEGF
- 100% de los pacientes requirieron cero o una inyección adicional
- 78% de los pacientes estuvieron completamente libres de inyecciones
El tratamiento fue bien tolerado con ningún evento adverso grave relacionado con el medicamento y sin casos de inflamación intraocular. Los pacientes mostraron una agudeza visual mejorada (BCVA) y un grosor retiniano central (CRT) mantenido. Los datos destacan el potencial de ABBV-RGX-314 como una opción de tratamiento efectiva de una sola vez para pacientes con AMD húmeda bilateral.
REGENXBIO (Nasdaq: RGNX)는 미국 안과학회(AAO) 회의에서 양측 습성 노인성 황반변성(습성 AMD) 환자에 대한 서브레티날 ABBV-RGX-314의
- 연간 항-VEGF 치료 부담 97% 감소
- 100%의 환자가 추가 주사가 0회 또는 1회만 필요했습니다
- 78%의 환자가 전혀 주사를 받지 않았습니다
치료는 약물과 관련된 심각한 부작용이 없고 안구 내 염증 사례가 없었으며 잘 견디는 것으로 나타났습니다. 환자들은 지속적인 최상의 교정 시력(BCVA)과 중앙망막 두께(CRT)를 보였습니다. 이 데이터는 ABBV-RGX-314가 양측 습성 AMD 환자에게 효과적인 단일 치료 옵션이 될 수 있는 가능성을 강조합니다.
REGENXBIO (Nasdaq: RGNX) a présenté données positives de l'étude secondaire de Phase II sur l'œil compagnon du traitement sous-rétinien ABBV-RGX-314 chez des patients atteints de dégénérescence maculaire liée à l'âge humide bilatérale (AMD humide) lors de la réunion de l'American Academy of Ophthalmology (AAO). Les résultats clés neuf mois après l'administration incluent :
- réduction de 97 % de la charge annuelle de traitement anti-VEGF
- 100 % des patients ont nécessité soit zéro, soit une injection supplémentaire
- 78 % des patients étaient complètement exempts d'injections
Le traitement a été bien toléré avec aucun événement indésirable grave lié au médicament et aucun cas d'inflammation intraoculaire. Les patients ont montré une acuité visuelle corrigée soutenue (BCVA) et une épaisseur rétinienne centrale (CRT) maintenue. Les données soulignent le potentiel d'ABBV-RGX-314 en tant qu'option thérapeutique efficace en une seule dose pour les patients atteints de AMD humide bilatérale.
REGENXBIO (Nasdaq: RGNX) präsentierte positive Daten aus der Phase-II-Studie zum Komplementär-Auge des subretinalen ABBV-RGX-314 bei Patienten mit bilateraler feuchter altersbedingter Makuladegeneration (feuchte AMD) auf der Jahrestagung der American Academy of Ophthalmology (AAO). Die wichtigsten Ergebnisse neun Monate nach der Verabreichung umfassen:
- 97% Reduktion der annualisierten Belastung durch Anti-VEGF-Behandlungen
- 100% der Patienten benötigten entweder null oder eine zusätzliche Injektion
- 78% der Patienten waren komplett injektionsfrei
Die Behandlung war gut verträglich mit keinen schwerwiegenden medikamentenbedingten Nebenwirkungen und ohne Fälle von intraokularen Entzündungen. Die Patienten zeigten eine nachhaltige bestkorrigierte Sehschärfe (BCVA) und eine stabile zentrale Netzhautdicke (CRT). Die Daten unterstreichen das Potenzial von ABBV-RGX-314 als einmalige wirksame Behandlungsoption für Patienten mit bilateraler feuchter AMD.
- 97% reduction in annualized anti-VEGF treatment burden at nine months
- 78% of patients were completely injection-free at nine months
- Sustained best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at nine months
- Well-tolerated with no drug-related serious adverse events
- No cases of intraocular inflammation without prophylactic steroids
- None.
Insights
The Phase II fellow eye sub-study results for ABBV-RGX-314 in bilateral wet AMD patients are highly promising. Key findings include:
- A
97% reduction in annualized anti-VEGF treatment burden 100% of patients requiring ≤1 supplemental injection78% of patients becoming injection-free
These outcomes suggest significant potential for reducing the treatment burden in wet AMD patients. The sustained BCVA and CRT, along with consistent protein levels in both treated eyes, indicate durable efficacy. Importantly, the therapy demonstrated a favorable safety profile with no serious adverse events or intraocular inflammation, even without prophylactic steroids.
This data, combined with previous long-term follow-up showing durable effects up to four years, positions ABBV-RGX-314 as a promising one-time treatment option for wet AMD. The ability to treat both eyes is a significant advancement in gene therapy for retinal diseases.
REGENXBIO's positive Phase II data for ABBV-RGX-314 could significantly impact the company's market position and financial outlook. Key considerations:
- Potential market disruption in wet AMD treatment, currently dominated by frequent anti-VEGF injections
- First-mover advantage in gene therapy for a common retinal disease
- Partnership with AbbVie enhances commercialization prospects
The
However, investors should consider the costs associated with completing pivotal trials and potential regulatory hurdles. The current market cap of
97% reduction in treatment burden at nine months after treatment with ABBV-RGX-314- Data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile
- Well tolerated with zero cases of intraocular inflammation in a setting of no prophylactic steroids
- Data highlight the potential of ABBV-RGX-314 to treat both eyes in wet AMD
"The results presented at AAO from the Phase II sub-study, the first to evaluate a gene therapy in fellow eyes for wet AMD, demonstrate that ABBV-RGX-314 could be a treatment for patients with bilateral disease and add to the already-robust data demonstrating ABBV-RGX-314's potential to impact the treatment paradigm for patients with wet AMD," said Curran Simpson, President and Chief Executive Officer of REGENXBIO. "With more treated patients and the longest-term data of any gene therapy program for wet AMD, REGENXBIO, with our partner AbbVie, are well-positioned to bring the first gene therapy to market with the hope of preserving long-term vision for millions of patients globally with wet AMD."
"The majority of our patients with wet AMD eventually have bilateral disease and face a substantial treatment burden with frequent lifelong injections in both eyes. This leads to suboptimal real-world vision outcomes with current standard of care," said Dr. Khanani. "The fellow eye dosing data with ABBV-RGX-314 is a milestone for the field of gene therapy for common retinal diseases, as this is the first time we have performed bilateral treatment for wet AMD patients. These results, combined with the durable treatment effect up to four years shown in long-term follow up, highlight the potential of ABBV-RGX-314 as a one-time effective treatment option for patients with wet AMD."
Data and Safety Summary
The fellow eye sub-study was designed to evaluate the safety and efficacy of a single dose (1.3x1011 GC/eye) of ABBV-RGX-314 using subretinal delivery in the fellow eye of previously treated patients. The second eye was treated with ABBV-RGX-314 approximately one year or more after administration of ABBV-RGX-314 in the first eye. This dose is being evaluated in the ongoing pivotal trials of ABBV-RGX-314 and is similar to one of the doses evaluated in the Phase I/IIa trial, which demonstrated durable treatment effect up to four years in a long-term follow up study.
The fellow eye sub-study data at nine months includes nine patients who received ABBV-RGX-314 using subretinal delivery in the Phase I/IIa or bridging studies and elected to receive treatment in their second eye. Prior to ABBV-RGX-314 administration, these patients had a high treatment burden in the fellow eye and had received an average of nine anti-VEGF injections in the year prior to entering the study, including anti-VEGF injections intended to be longer-lasting treatments.
At nine months post-administration of ABBV-RGX-314, key findings from the Phase II fellow eye sub-study include:
97% reduction in annualized anti-VEGF treatment burden100% of patients required either zero or one supplemental injection78% of patients were completely injection-free
Additionally, patients demonstrated sustained best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at nine months. ABBV-RGX-314 produced similar levels of aqueous protein in both treated eyes.
As of September 11, 2024, ABBV-RGX-314 was well tolerated in the treated fellow eye with no drug related serious adverse events. No cases of intraocular inflammation, chorioretinitis, vasculitis, occlusion or hypotony were observed. No prophylactic steroids were used in this trial, other than those typically used in vitrectomy surgery. Common adverse events included mild retinal pigmentary changes occurring in periphery and post-operative conjunctival hemorrhage, which all resolved within days to weeks.
Data presented is available on the "Publications" section of the REGENXBIO website at www.regenxbio.com.
About ABBV-RGX-314
ABBV-RGX-314, being developed in collaboration with AbbVie, is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. ABBV-RGX-314 consists of the NAV® AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). ABBV-RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the accumulation of fluid in the retina.
REGENXBIO is advancing research in two separate routes of administration of ABBV-RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. REGENXBIO has licensed certain exclusive rights to the SCS Microinjector® from Clearside Biomedical, Inc. to deliver gene therapy treatments to the suprachoroidal space of the eye.
About Wet AMD
Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations and clinical trials. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2023, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the
Zolgensma® is a registered trademark of Novartis Gene Therapies. SCS Microinjector® is a trademark of Clearside Biomedical, Inc. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACT:
Dana Cormack
Corporate Communications
DCORMACK@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-presents-positive-data-from-the-phase-ii-study-of-subretinal-abbv-rgx-314-in-patients-with-bilateral-wet-amd-at-aao-2024-302281503.html
SOURCE REGENXBIO Inc.
FAQ
What were the key results of REGENXBIO's Phase II study for ABBV-RGX-314 in wet AMD patients?
How did ABBV-RGX-314 (RGNX) perform in terms of safety in the wet AMD Phase II study?
What is the potential impact of REGENXBIO's ABBV-RGX-314 (RGNX) for bilateral wet AMD patients?